Donald Notman Sells 6,301 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Donald Notman sold 6,301 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $7.84, for a total transaction of $49,399.84. Following the completion of the transaction, the insider now directly owns 204,563 shares in the company, valued at $1,603,773.92. This represents a 2.99 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Donald Notman also recently made the following trade(s):

• On Tuesday, February 4th, Donald Notman sold 11,119 shares of Ocular Therapeutix stock. The stock was sold at an average price of $7.81, for a total value of $86,839.39.

Ocular Therapeutix Price Performance

Shares of OCUL opened at $8.13 on Thursday. Ocular Therapeutix, Inc. has a one year low of $4.06 and a one year high of $11.77. The stock’s fifty day moving average is $8.57 and its 200-day moving average is $9.01. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -6.16 and a beta of 1.22.

Analysts Set New Price Targets

Several brokerages have weighed in on OCUL. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, December 3rd. Scotiabank began coverage on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $16.71.

Hedge Funds Weigh In On Ocular Therapeutix

Large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Ocular Therapeutix by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 1,015 shares during the period. Algert Global LLC acquired a new stake in Ocular Therapeutix in the second quarter worth approximately $69,000. Capital Performance Advisors LLP bought a new position in Ocular Therapeutix during the 3rd quarter valued at $70,000. Palumbo Wealth Management LLC acquired a new position in shares of Ocular Therapeutix during the 4th quarter valued at $100,000. Finally, Diversified Trust Co bought a new stake in shares of Ocular Therapeutix in the 3rd quarter worth $106,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.